Oriola Reports Continued Product Segment Sales Growth as Group Profitability Holds Steady in Q2 2026
Oriola continued to deliver growth in its Products segment during the second quarter of 2026, while group profitability remained broadly stable compared with the same period last year.
The Finnish healthcare and pharmaceutical services company reported net sales of EUR 51.8 million for the quarter, representing growth of 1.7%. Adjusted EBITDA was EUR 8.1 million, unchanged from EUR 8.1 million in the second quarter of 2025. The adjusted EBITDA margin was 15.6%, compared with 15.8% a year earlier.
The results reflect mixed performance across Oriola’s business segments. The company continued to benefit from positive sales development in its Finnish wholesale business, while volumes in speciality pharmaceutical flows remained strong. However, demand for pharmaceutical distribution services was weaker than anticipated in some areas.
Higher freight costs, driven in part by increased fuel prices, also placed pressure on profitability during the quarter.
Oriola said measures already implemented are expected to help mitigate the impact of higher logistics costs in the coming quarters.
Finnish Wholesale Business Continues to Support Growth
The company’s Finnish wholesale business continued to show positive development during the second quarter.
Growth was supported by activity across e-commerce, retail, and pharmacy channels. Oriola also continued the renewal of its own-brand portfolio, with several refreshed brands achieving double-digit sales growth.
The company’s own brands are an important part of its product offering and provide opportunities to strengthen customer engagement and expand sales across different channels.
Sales of special-licensed medicines also remained strong during the quarter.
These medicines can require companies to respond quickly to market opportunities, and Oriola said its ability to act with agility supported sales development.
The continued growth in Finland helped offset weaker performance in certain other areas of the business.
Services Segment Faces Mixed Market Conditions
The Services segment experienced a more challenging quarter.
Net sales declined by 2.0%, reflecting weaker performance in pharmaceutical distribution in Sweden and advisory services.
Volume growth was lower during the quarter, partly because of market developments in Sweden’s weight-loss product segment.
The Swedish market continued to experience growth in weight-loss products, but Oriola’s customer portfolio is less strongly positioned in this area.
At the same time, speciality flows continued to perform well.
Volumes in areas such as vaccines, exports, and animal health remained at a higher level than during the same period a year earlier.
These speciality flows continue to represent important areas of opportunity for Oriola because they support differentiated services and can provide additional growth opportunities beyond traditional pharmaceutical distribution.
Adjusted EBITDA in the Services segment declined to EUR 9.0 million from EUR 9.3 million in the second quarter of 2025.
The decline was primarily linked to increased freight costs.
Products Segment Delivers Double-Digit Sales Growth
The Products segment was one of the strongest areas of performance during the quarter.
Net sales increased by 11.2%, supported by growth in both the Finnish wholesale business and the dose dispensing business.
The performance reflects continued demand across several sales channels.
E-commerce, retail, and pharmacy customers contributed to the positive development of the Finnish wholesale business.
The renewal of Oriola’s own brands also supported the segment’s performance.
Several of the renewed brands achieved double-digit sales growth, demonstrating the potential of the company’s portfolio renewal strategy.
Sales of special-licensed medicines were also strong.
The company’s ability to respond quickly to changing market opportunities helped support performance in this area.
Despite the strong sales growth, adjusted EBITDA in the Products segment declined slightly to EUR 1.0 million from EUR 1.1 million.
The decline was primarily attributed to higher operating expenses.
The result highlights the importance of maintaining cost discipline as the company works to convert sales growth into improved profitability.
Supply Chain Operations Remain Stable
Oriola’s supply chain operations remained stable during the second quarter despite an uncertain operating environment.
The company also made several improvements to efficiency.
One important development involved vaccine deliveries to Northern Sweden.
Oriola successfully transitioned these deliveries from air freight to road transportation.
The change is expected to improve both sustainability and cost efficiency during the second half of the year.
Moving certain transportation flows from air to road can help reduce logistics costs while also lowering the environmental impact associated with transportation.
The change forms part of Oriola’s broader efforts to improve supply chain efficiency.
However, higher freight costs continued to affect the business during the quarter.
The increase was linked in part to higher fuel prices.
In Sweden, inventory levels also increased as pharmaceutical companies continued to build stocks to support product availability.
Maintaining adequate inventory levels can be important in the pharmaceutical sector, where supply disruptions can have significant consequences for pharmacies, healthcare providers, and patients.
At the same time, higher inventory levels can increase working capital requirements and create additional operational complexity.
Oriola continues to manage this balance as market conditions evolve.
Kronans Apotek Reports Continued Revenue Growth
Oriola’s joint venture company, Kronans Apotek, delivered another quarter of revenue growth.
Sales increased by 5.3% year-on-year in local currency despite continued competitive pressure in the Swedish pharmacy market.
Kronans Apotek held a market share of 21.1% at the end of the quarter.
Profitability also improved compared with the second quarter of 2025.
The company has established a commercial and operational improvement agenda designed to strengthen its financial performance.
During the second quarter, Kronans Apotek implemented initiatives across pricing, commercial execution, and pharmacy operations.
Additional initiatives have been agreed for the third quarter.
The measures are intended to support gross profit development, improve operational efficiency across the pharmacy network, and create a more efficient cost base over time.
Kronans Apotek remains focused on sustainable profitable growth.
The company is continuing to execute its strategic priorities while operating in a highly competitive retail pharmacy environment.
The ongoing improvement program is expected to support future profitability as the business continues to develop its commercial operations.
ERP Programme Under Review
Oriola is also continuing its programme to renew its enterprise resource planning and warehouse management systems.
Following the first deployment in Sweden, the company is reviewing findings and amending the programme and its timeline.
The design phase for the second deployment in Sweden is ongoing.
The amendment to the programme does not change Oriola’s strategic objectives.
The company continues to expect the investment to support long-term operational efficiency, harmonize processes and systems, and help meet evolving customer and business requirements.
Large-scale ERP and warehouse management projects can involve significant operational complexity.
They often require changes to technology systems, processes, data management, and employee workflows.
The experience gained from the initial Swedish deployment is expected to help inform the next phase of the programme.
Oriola’s long-term objective remains to create a more integrated and efficient operational platform.
New Automated Distribution Centre Progresses in Finland
Construction of Oriola’s new distribution centre in Järvenpää, Finland, is progressing according to plan.
The highly automated facility is expected to become an important part of the company’s future distribution infrastructure.
During the second quarter, the construction project reached an important milestone as installation of the frame structure began.
Oriola has also appointed a partner for the automation solution.
The new facility is intended to support improved efficiency and modernize the company’s distribution capabilities.
Automation can help improve warehouse productivity, support more accurate order handling, and strengthen operational scalability.
As pharmaceutical distribution becomes increasingly complex, modern distribution infrastructure can play an important role in meeting customer requirements.
The Järvenpää project represents a long-term investment in Oriola’s Finnish operations.
Focus on Profitable Growth in the Second Half of 2026
Looking ahead to the second half of the year, Oriola will continue to focus on profitable growth.
The company expects net sales growth to be supported by market expansion, continued strong performance in speciality flows, new customers, and value-added services.
Export and vaccine distribution are expected to remain important areas of opportunity.
The positive development of the Finnish wholesale business is also expected to continue.
Oriola’s differentiated offering is expected to support its ability to serve customers across multiple channels and product categories.
The company also expects its own-brand portfolio development to contribute to future performance.
Cost Control Remains a Priority
Cost discipline will remain a key focus for Oriola during the second half of the year.
The company expects freight cost control to improve as previously implemented measures begin to have a greater impact.
Several efficiency initiatives introduced during the first half of the year are also expected to contribute positively.
These include more accurate workload planning using artificial intelligence and improved route planning in Sweden.
The use of AI for workload planning can help companies better align resources with demand.
Improved route planning can also help reduce inefficiencies in transportation operations.
Together, these initiatives are intended to support more efficient use of resources and reduce unnecessary costs.
In advisory services, restructuring measures have been implemented to reduce personnel expenses.
Oriola has also identified additional cost-saving opportunities.
The company said it will continue to maintain strict cost control while pursuing growth opportunities.
Balancing Growth and Efficiency
Oriola’s second-quarter results demonstrate the importance of balancing revenue growth with operational efficiency.
The Products segment delivered strong double-digit sales growth, but increased operating expenses limited the impact on profitability.
Meanwhile, higher freight costs affected performance in the Services segment.
The company is therefore focusing on both sides of the equation.
Growth initiatives are intended to increase sales and expand market opportunities, while efficiency initiatives are designed to protect margins and improve profitability.
The company’s investments in technology, automation, supply chain efficiency, and process improvement are expected to support this strategy over the longer term.
Building a More Efficient Healthcare Distribution Platform
Oriola operates in an increasingly complex healthcare and pharmaceutical environment.
Pharmaceutical supply chains must manage changing demand, regulatory requirements, product availability, logistics costs, and customer expectations.
The company’s focus on speciality flows, digital channels, automation, and operational efficiency reflects the changing nature of the industry.
The new Järvenpää distribution centre and ERP modernization programme are part of a broader effort to strengthen infrastructure.
At the same time, the company is continuing to develop its commercial offering through own-brand renewal, value-added services, and new customer relationships.
These initiatives are intended to create a stronger foundation for future growth.
Outlook for the Remainder of the Year
Oriola enters the second half of 2026 with several positive developments across its business.
The Finnish wholesale business continues to grow.
Speciality flows remain strong.
Kronans Apotek continues to increase revenue and improve profitability.
The company is also advancing major infrastructure and technology projects.
However, challenges remain.
Freight costs continue to place pressure on margins, while market conditions in some pharmaceutical distribution areas are weaker than expected.
The company will therefore need to continue balancing investment and growth with cost discipline.
The measures implemented during the second quarter are expected to support improved cost control in the coming quarters.
Continued Focus on Long-Term Performance
Oriola’s second-quarter performance reflects a company continuing to adapt to a changing healthcare market.
Net sales increased by 1.7% to EUR 51.8 million, while adjusted EBITDA remained stable at EUR 8.1 million.
The Products segment delivered strong growth, particularly in Finland, while the Services segment faced pressure from weaker pharmaceutical distribution demand and higher freight costs.
At the same time, speciality flows continued to perform well, Kronans Apotek achieved further revenue growth, and important investments in technology and distribution infrastructure progressed.
The company’s priorities for the remainder of 2026 are clear: continue delivering profitable growth, improve cost control, strengthen supply chain efficiency, and advance strategic investments.
As Oriola moves forward, its ability to combine commercial growth with operational discipline will be central to its performance.
The company’s investments in digital systems, automation, AI-supported planning, and supply chain optimization are expected to support long-term efficiency.
Meanwhile, continued growth in Finnish wholesale operations, speciality pharmaceutical flows, value-added services, and new customer relationships could provide further opportunities for expansion.
The second quarter demonstrates that Oriola continues to operate in a dynamic environment, but its focus on efficiency, innovation, and customer value provides a foundation for continued progress through the remainder of 2026.
Source link: https://www.oriola.com/
